AI scribe subscriptions are hard to compare when one price covers note drafting and another includes EHR integration, coding or order staging. Contract length, implementation and data handling can change the real cost further. For an Australian clinic evaluating Suki, the buying decision needs a line-by-line quote and clear local evidence. Lyrebird Health publishes this guide and is included as an alternative. The comparison applies the same public fields to both vendors: pricing and entry path, documentation scope, integrations, standard contract position, privacy and data handling, and evidence.

Suki AI pricing is available by quote

As at 17 September 2026, Suki does not publish a standard subscription price for Suki Compose, its broader clinician workflow features or Suki Dictation. Its public buying path leads to a sales conversation. Suki's service terms define an Order Form as the quote or document that sets the purchased subscriptions and pricing.

That makes the signed quote the reliable answer to how much Suki costs. Monthly figures on third-party directories may describe an earlier offer and should not be treated as a current price.

Is Suki AI free?

As at 17 September 2026, the Australian App Store listing labels the iPhone app as free to download. That covers app acquisition, not access to a Suki subscription. The listing does not show in-app subscription prices, and Suki's public product pages direct prospective customers to sales.

A pilot may be negotiable. Its duration, included users, data handling, acceptance criteria and conversion to a paid term should be written into the proposal.

What the Suki quote should include

Suki markets several product scopes. A useful quote names the exact product and feature set rather than using “Suki” as one undifferentiated line item.

Suki

The proposal should also answer:

• Who counts as a billable user? Define full-time clinicians, part-time clinicians, locums, trainees, nurses and administrators, along with any minimum seat commitment.
• What usage is included? Record encounter, dictation, generated-note, regeneration, storage and overage rules, even if the answer is “unlimited”.
• What EHR work is required? Name the production and test environments, launch method, patient matching, data pulled into Suki, write-back destination and recovery process when an integration fails.
• What services cost extra? Separate implementation, template configuration, integration, training, premium support and future feature modules.
• When does billing start? Tie the date to agreed technical and clinical acceptance criteria rather than the sales signature alone.
• How does the clinic leave? Record notice dates, renewal price, data export, pending-note handling, access after termination and verified deletion.

Calculate the total cost beyond the licence rate

A monthly seat price omits the work needed to make a clinical system usable. Compare proposals on first-year and steady-state cost.

First-year cost = recurring licences + implementation + integration and EHR charges + training and change management + support tiers + foreign exchange and tax + exit or transition costs

For a multi-clinician practice, do not multiply a quoted seat rate until the unit is clear. Named-user, active-user, encounter-based and organisation-wide pricing behave differently when rosters change.

The most useful denominator is an approved clinical output. During a pilot, calculate total cost per clinician and per clinician-approved note, then track:

• minutes from the end of the consult to sign-off;
• clinically meaningful omissions, unsupported statements and contradictions;
• the number of drafts needing substantial correction;
• successful patient matching and write-back;
• clinician adoption by feature, including voice commands and order staging; and
• support time and unresolved incidents.

These measures show whether an integrated feature actually removes work in the clinic. A feature that clinicians do not adopt has little economic value, even when it is included in the licence.

Australian buyers need local answers

Suki's app can be downloaded from the Australian App Store, but that listing does not establish an Australian subscription, sales entity, onboarding team, support coverage or hosting arrangement. As at 17 September 2026, the listing says the dedicated account manager is located in the United States.

Data location and contract controls

Suki's privacy policy allows personal data to be transferred to its offices, servers and authorised third parties in the United States. It also says that, unless a separate agreement governs the service, Suki may retain or destroy collected information at its discretion after use ends.

The public service terms allow customer data to be accessed for system tuning, grammar tuning and training acoustic and other models. Suki Compose separately states that only anonymised data is used for model training. The Business Associate Agreement, Order Form and privacy schedule should resolve the rule that applies to the Australian deployment, including subprocessors, countries, retention, deletion and training use.

Under APP 8 cross-border guidance, an APP entity must take reasonable steps before disclosing personal information to an overseas recipient. The Australian entity can remain accountable for an overseas recipient's handling in some circumstances. US Health Insurance Portability and Accountability Act (HIPAA) commitments do not settle that Australian assessment.

Coding and regulatory scope

Suki's clinician workflow names International Classification of Diseases, Tenth Revision (ICD-10), Hierarchical Condition Category (HCC), Current Procedural Terminology (CPT) and evaluation and management (E/M) coding. Its public material does not establish support for Medicare Benefits Schedule (MBS) item selection or ICD-10-AM. An Australian proposal should name each supported local coding workflow and keep final coding decisions with the clinician or qualified coder.

The TGA's digital-scribe guidance distinguishes transcription and translation from analysis or interpretation that has a therapeutic purpose. A configured product that generates a diagnosis, differential diagnosis or treatment recommendation not stated by the clinician can be a medical device and require Australian Register of Therapeutic Goods inclusion. Because Suki also markets patient summaries for clinical reasoning and ambient order staging, an Australian buyer should obtain a written intended-purpose and regulatory position for the exact licensed configuration.

What independent evidence says about value

A 2026 KLAS evaluation examined Suki at three large US health systems in ambulatory workflows. Its public summary reports reduced documentation burden, time savings, improved E/M coding and financial gains at all three organisations. The full dataset requires login, and KLAS warns that the findings are not conclusive for an entire client base.

As at 17 September 2026, the US App Store displays a 4.1/5 score from 66 ratings. Visible positive reviews praise note speed and Epic or Cerner integration. One critical oncology review reports drug-recognition problems, omitted detail and content placed in the wrong section. These are self-selected US app reviews, so they are pilot prompts rather than a forecast for an Australian practice. As at the same date, the Australian App Store does not have enough ratings or reviews to display an overview.

This evidence supports a local pilot of the integrated workflow, especially where Suki already has a deep EHR connection. It does not supply a market price or prove a return for a different specialty, EHR or country.

Suki and Lyrebird compared for Australian clinics

Both products can turn a consult into a draft note for clinician review. Their public buying paths and local evidence differ.

Lyrebird

The Gold Coast evaluation adds Australian outpatient evidence, but it does not establish Lyrebird's return on investment. It cannot show whether licence, implementation and governance costs will be offset in another clinic. A buyer should apply the same local cost-per-approved-note and workflow measures to Lyrebird during an evaluation.

Suki may suit a health system already using one of its named deep EHR integrations and seeking voice-led work across pre-visit, encounter and post-visit tasks. Its value depends on the quote including those capabilities and on clinicians adopting them.

Lyrebird may suit Australian GPs, specialists and practice groups that want a self-service evaluation, public plan structure and downstream document workflows alongside clinical notes. Its current pricing and integration catalogue set out the available plans and named system connections.

Questions to send Suki sales

Ask for written answers that can be attached to the proposal:

1. Which Suki products and functions are included, and which require separate licences?
2. What is the price unit, minimum user commitment, invoice currency, tax treatment and renewal increase?
3. Is a pilot available, and when does the paid term begin?
4. What usage, storage or device limits apply, and what triggers an overage?
5. What will Suki read from and write to the practice's exact EHR version?
6. Which implementation, EHR-vendor, training and support costs sit outside the licence?
7. Which Australian team will provide onboarding, account management and support, during what hours?
8. Where will audio, transcripts, prompts, notes and logs be processed and retained, and which subprocessors receive them?
9. How are customer and patient data used for product or model improvement, and which signed term controls?
10. What Australian privacy, security, coding and TGA evidence applies to the configured functions?
11. What notice stops renewal, and what data return, deletion and transition assistance follows termination?

A Suki quote is ready to compare only when it answers those questions. For an Australian practice, local workflow and governance evidence should carry the same weight as the licence figure.

If you want to compare that enterprise proposal with an Australian clinical AI workflow for notes and the documents that follow, Contact us.